256 related articles for article (PubMed ID: 27768593)
1. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
Redko B; Tuchinsky H; Segal T; Tobi D; Luboshits G; Ashur-Fabian O; Pinhasov A; Gerlitz G; Gellerman G
Oncotarget; 2017 Jan; 8(1):757-768. PubMed ID: 27768593
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
3. Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma models.
Yacobovich S; Tuchinsky L; Kirby M; Kardash T; Agranyoni O; Nesher E; Redko B; Gellerman G; Tobi D; Gurova K; Koman I; Ashur Fabian O; Pinhasov A
Oncotarget; 2016 Sep; 7(39):63549-63560. PubMed ID: 27556860
[TBL] [Abstract][Full Text] [Related]
4. Anti-Cancer Effects of Cyclic Peptide ALOS4 in a Human Melanoma Mouse Model.
Levi B; Yacobovich S; Kirby M; Becker M; Agranyoni O; Redko B; Gellerman G; Pinhasov A; Koman I; Nesher E
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502483
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel dual-cyclic RGD peptides for α
Liu J; Cheng X; Tian X; Guan D; Ao J; Wu Z; Huang W; Le Z
Bioorg Med Chem Lett; 2019 Apr; 29(7):896-900. PubMed ID: 30732943
[TBL] [Abstract][Full Text] [Related]
6. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery.
Gilad Y; Noy E; Senderowitz H; Albeck A; Firer MA; Gellerman G
Bioorg Med Chem; 2016 Jan; 24(2):294-303. PubMed ID: 26719208
[TBL] [Abstract][Full Text] [Related]
8. Cyclic RGD and
Panzeri S; Arosio D; Gazzola S; Belvisi L; Civera M; Potenza D; Vasile F; Kemker I; Ertl T; Sewald N; Reiser O; Piarulli U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339382
[TBL] [Abstract][Full Text] [Related]
9. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
10. Structure-Activity Relationship of RGD-Containing Cyclic Octapeptide and αvβ3 Integrin Allows for Rapid Identification of a New Peptide Antagonist.
Silva A; Xiao W; Wang Y; Wang W; Chang HW; Ames JB; Lam KS; Zhang Y
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349271
[TBL] [Abstract][Full Text] [Related]
11. α
Koh B; Park SB; Yoon E; Yoo HM; Lee D; Heo JN; Ahn S
J Pharm Sci; 2019 Nov; 108(11):3704-3712. PubMed ID: 31348936
[TBL] [Abstract][Full Text] [Related]
12. A new cyclic RGD peptide dimer for integrin αvβ3 imaging.
Ma H; Hao P; Zhang L; Ma C; Yan P; Wang RF; Zhang CL
Eur Rev Med Pharmacol Sci; 2016; 20(4):613-9. PubMed ID: 26957261
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.
Chen X; Plasencia C; Hou Y; Neamati N
J Med Chem; 2005 Feb; 48(4):1098-106. PubMed ID: 15715477
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.
Saraf P; Li X; Wrischnik L; Jasti B
Pharm Res; 2015 Sep; 32(9):3087-101. PubMed ID: 26063045
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy.
Conway CL; Walker I; Bell A; Roberts DJ; Brown SB; Vernon DI
Photochem Photobiol Sci; 2008 Mar; 7(3):290-8. PubMed ID: 18389145
[TBL] [Abstract][Full Text] [Related]
16. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
Wu H; Jiang J; Xu H; Li Q; Cai J
Expert Opin Ther Pat; 2016; 26(1):131-7. PubMed ID: 26560186
[TBL] [Abstract][Full Text] [Related]
17. Novel cilengitide-based cyclic RGD peptides as αvβ
Meena CL; Singh D; Weinmüller M; Reichart F; Dangi A; Marelli UK; Zahler S; Sanjayan GJ
Bioorg Med Chem Lett; 2020 Apr; 30(8):127039. PubMed ID: 32094009
[TBL] [Abstract][Full Text] [Related]
18. Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.
Karageorgis A; Claron M; Jugé R; Aspord C; Thoreau F; Leloup C; Kucharczak J; Plumas J; Henry M; Hurbin A; Verdié P; Martinez J; Subra G; Dumy P; Boturyn D; Aouacheria A; Coll JL
Mol Ther; 2017 Feb; 25(2):534-546. PubMed ID: 28153100
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.
Pilkington-Miksa M; Arosio D; Battistini L; Belvisi L; De Matteo M; Vasile F; Burreddu P; Carta P; Rassu G; Perego P; Carenini N; Zunino F; De Cesare M; Castiglioni V; Scanziani E; Scolastico C; Casiraghi G; Zanardi F; Manzoni L
Bioconjug Chem; 2012 Aug; 23(8):1610-22. PubMed ID: 22770429
[TBL] [Abstract][Full Text] [Related]
20. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
